Merit Medical Systems (NASDAQ:MMSI) Price Target Raised to $110.00

Merit Medical Systems (NASDAQ:MMSI) had its price target hoisted by JPMorgan Chase & Co. from $95.00 to $110.00 in a research report report published on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical instruments supplier’s stock.

A number of other analysts also recently issued reports on the company. Zacks Research downgraded Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. Robert W. Baird set a $98.00 price target on shares of Merit Medical Systems in a research report on Friday, July 31st. Wells Fargo & Company boosted their price objective on Merit Medical Systems from $83.00 to $92.00 and gave the company an “equal weight” rating in a report on Friday. Barrington Research set a $114.00 price target on Merit Medical Systems in a report on Friday, July 31st. Finally, Needham & Company LLC increased their price target on Merit Medical Systems from $101.00 to $106.00 and gave the company a “buy” rating in a report on Friday. Eight analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.55.

Merit Medical Systems Price Performance

MMSI opened at $86.24 on Friday. The firm has a market cap of $5.15 billion, a P/E ratio of 32.42, a PEG ratio of 2.15 and a beta of 0.51. Merit Medical Systems has a fifty-two week low of $59.74 and a fifty-two week high of $94.85. The firm has a 50-day moving average of $88.60 and a 200 day moving average of $77.14. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.05 and a current ratio of 4.52.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.08. The business had revenue of $416.24 million during the quarter, compared to analysts’ expectations of $410.56 million. Merit Medical Systems had a return on equity of 14.12% and a net margin of 9.94%. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.92 earnings per share. On average, research analysts expect that Merit Medical Systems will post 3.84 EPS for the current year.

Institutional Investors Weigh In On Merit Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Boston Trust Walden Corp boosted its holdings in Merit Medical Systems by 12.4% in the third quarter. Boston Trust Walden Corp now owns 531,396 shares of the medical instruments supplier’s stock valued at $45,822,000 after purchasing an additional 58,540 shares during the period. Chicago Partners Investment Group LLC acquired a new position in shares of Merit Medical Systems in the third quarter worth about $213,000. Mountain Pacific Investment Advisers LLC grew its stake in Merit Medical Systems by 88.8% during the 3rd quarter. Mountain Pacific Investment Advisers LLC now owns 38,048 shares of the medical instruments supplier’s stock worth $3,281,000 after buying an additional 17,899 shares during the last quarter. Salomon & Ludwin LLC boosted its position in shares of Merit Medical Systems by 140.8% during the 3rd quarter. Salomon & Ludwin LLC now owns 537 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 314 shares in the last quarter. Finally, Vise Technologies Inc. raised its position in Merit Medical Systems by 15.5% during the third quarter. Vise Technologies Inc. now owns 19,134 shares of the medical instruments supplier’s stock valued at $1,650,000 after acquiring an additional 2,567 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems News Summary

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong Q3 earnings beat expectations. Merit reported third-quarter revenue of $416.2 million, up 8.4% year over year and ahead of the $410.6 million consensus estimate. Non-GAAP EPS was $1.12 versus expectations of $1.04, while GAAP EPS rose 51% to $0.70. Merit Medical Q3 2026 results
• Positive Sentiment: Profitability and cash generation improved. Organic constant-currency revenue increased 9%, GAAP operating margin expanded to 14.1% from 11.1%, and year-to-date operating cash flow reached $175.2 million, with $129.5 million in free cash flow.
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 earnings outlook following the strong quarter, supporting expectations for continued growth. Merit Medical raises 2026 guidance
• Positive Sentiment: Analysts raised targets. BTIG Research lifted its target from $105 to $110 and maintained a buy rating. Wells Fargo raised its target from $83 to $92, although it retained an equal-weight rating. Analysts raise Merit Medical price targets
• Positive Sentiment: Cardiac-therapy capabilities expanded. Merit acquired Solo Pace, adding temporary pacing technology designed for patients with aortic stenosis and strengthening its TAVR-related product portfolio. Merit Medical acquires Solo Pace
• Neutral Sentiment: Valuation remains a consideration. With the stock trading at roughly 36 times earnings and near its 52-week high, investors may be demanding continued execution, leaving limited room for disappointment.
• Negative Sentiment: Some caution remains among analysts. Wells Fargo’s equal-weight rating and the company’s narrowed sales outlook temper the bullish impact of the earnings beat and guidance increase.

About Merit Medical Systems

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.